Merrimack Pharmaceuticals Inc : Merrimack names Richard Peters as president and CEO . Merrimack Pharmaceuticals Inc - Peters replaces Gary Crocker, chairman and interim president and CEO .Merrimack Pharmaceuticals Inc - Gary Crocker will remain chairman of board.
Ixico Plc :Appointment of Giulio Cerroni as CEO.
Nivalis Therapeutics Inc : Nivalis Therapeutics announces corporate restructuring . Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees . Nivalis Therapeutics Inc - Board of directors has approved a restructuring plan as part of company's initiative to explore strategic alternatives . Says estimates that it will incur cash severance costs of approximately $3 million . Nivalis Therapeutics - Co estimates it will incur cash severance costs of approximately $3 million, which are expected to be paid during first half of 2017 . Nivalis Therapeutics Inc says Congleton will be stepping down from his role as president and chief executive officer effective January 15, 2017 . Says reduction in force is intended to preserve company's cash while it assesses various strategic alternatives . Nivalis Therapeutics - Co currently projects that it will have approximately $45-$47 million of net cash available for potential strategic transaction . Nivalis Therapeutics - Reduction in workforce includes Jon Congleton, president & CEO, and David Rodman, M.D., chief medical officer .Board has appointed Michael Carruthers, co's chief financial officer, as interim president, effective Jan 15, 2017.
Invitae Corp : Sean George appointed as chief executive officer .Current chairman and chief executive officer Randy Scott will become executive chairman of board of directors.
Insys Therapeutics Inc : Insys Therapeutics announces retirement of Dr. John n. Kapoor as ceo and chairman; appoints Dr. Santosh vetticaden as interim CEO and Steven Meyer as chairman of the board .Insys Therapeutics inc - Kapoor will remain a member of board.
Immunomedics Inc : Immunomedics announces reconstituted board of directors and leadership succession plan . Immunomedics Inc - Announces chairman and CEO succession plans . Immunomedics Inc - Effective June 30, 2017, Jason Aryeh will assume role of chairman of Immunomedics board. . Immunomedics Inc - David M. Goldenberg, current chairman, will transition his role, effective June 30, 2017 .Immunomedics Inc - Board will immediately initiate a search for a new CEO.
Chengzhi Shareholding Co Ltd <000990.SZ> :Says President Zheng Chengwu resigns due to change in job role.
MDxHealth SA : MDxHealth announces preliminary update on 2016 results and appointment of CFO . Expects to achieve upgraded market guidance for FY 2016 financial results following continued strong growth of ConfirmMDx and early adoption of SelectMDx during year . Underlying earnings before interest, taxes, depreciation and amortization (ebidta) are also expected to improve compared to 2015 . Full-Year 2016 results will reflect initial sales of company's SelectMDx for prostate cancer "liquid biopsy" test . Co previously upgraded its expected full-year revenue growth to more than 60 percent compared with its initial guidance predicting growth of 30-50 percent over 2015 .MDxHealth announces appointment of Jean-Marc Roelandt as chief financial officer with effect from January 15, 2017.
Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals Inc and Achieve Life Science, Inc announce definitive merger agreement . Oncogenex - upon completion of proposed merger, achieve's equity holders are expected to own 75 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - combined company's executive management team will be led by Rick Stewart, chairman of Achieve . Oncogenex Pharmaceuticals - expected to distribute to its stockholders contingent value rights (CVRS) for 80 pct of any net proceeds of certain payments . Oncogenex Pharmaceuticals Inc - board of directors of combined company is expected to consist of seven members . Following completion of merger, Oncogenex Pharmaceuticals Inc ill be renamed Achieve Life Sciences Inc . Oncogenex - after completion, current stockholders of oncogenex are expected to own remaining 25 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - "efforts will continue to establish a strategic partnership to further development of apatorsen" .Oncogenex Pharmaceuticals Inc - transaction has been approved unanimously by boards of directors of both companies.
Targovax ASA : Announces appointment of Erik Digman Wiklund CFO . Erik Digman Wiklund will take up the position in April 2017 .Previous CFO, Oystein Soug, was appointed as Targovax's CEO on Nov. 2 2016.